Michael Tesar, Ph.D., Head of Discovery & Research, Affimed GmbH, Heidelberg, Germany.
Michael joined Affimed in 2016. He is responsible for the development of novel antibody therapeutics based on Affimed’s proprietary bispecific NK cell-engaging antibody platform, called ROCK® (Redirected optimized cell killing). Prior to Affimed he held positions at MorphoSys and Pierre Fabre as group leader in antibody discovery and preclinical development. He graduated from the University of Stuttgart in 1990 and conducted his Ph.D. research at the former Federal Research Center for Virus Diseases of Animals in Tübingen. After several years of post-doctoral training at the University of Utah and California he joined the Helmholtz Center for Infection Research in Braunschweig. Along his career he developed an expertise in antibody engineering and antibody display technologies.